Abstract #4957
Assessing redox changes induced by treatment with pharmacological ascorbate in glioblastoma using T2* and QSM
Chu-Yu Lee1, Michael S Petronek2, Cameron M Cushing3, Garry R Buettner2, Joel J St-Aubin2, Varun Monga4, John M Buatti2, Joseph J Cullen5, Douglas R Spitz2, Bryan G Allen2, and Vincent A Magnotta1
1Department of Radiology, The University of Iowa, Iowa City, IA, United States, 2Department of Radiation Oncology, Free Radical and Radiation Biology Program, The University of Iowa, Iowa City, IA, United States, 3Skope Magnetic Resonance Technologies AG, Zurich, Switzerland, 4Department of Internal Medicine, The University of Iowa, Iowa City, IA, United States, 5Department of Surgery, The University of Iowa, Iowa City, IA, United States
Synopsis
Pharmacological ascorbate (P-AscH-), as an adjuvant to standard treatment for glioblastoma, may selectively enhance cancer cell killing. The mechanisms of P-AscH- have been associated with redox changes in the labile iron pool. This study applies T2* and QSM to assess the redox changes in 40 glioblastoma patients receiving standard treatment and adjuvant P-AscH-. The results demonstrate an increase in T2* values and a decrease in QSM values within contrast-enhancing lesions 1 hour after P-AscH- infusion. These changes in T2* and QSM may result from the redox changes by P-AscH-, supporting the potential for imaging assessment of response to P-AscH-.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
